michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
It's roughly 45%, but obviously depends a lot by business. Pest elimination is much lower as you can imagine and in some industrial businesses, it might be higher but in average it's 45% for the company.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
While we don't provide forecasts or guidance, William, but what we are seeing in the first two months of this year seems quite positive. The order numbers seems, it's much better than what we had in the last year or two. So we believe the first quarter, which will be super good for us. One of the reasons for that is probably because of the implementation nationwide for the National VI A emission standard. So, that will be implemented 1st July 2021. So that could have resulted in some pre-buy effects that is causing some the higher order numbers we're seeing now in January, February.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I couldn't give you a definitive timeline other than we have certain milestones that need to be met by way of technology assessment and things of that nature. As they pan themselves out, we'll check the box and then proceed accordingly. But I couldn't give you a definitive timeline because there's elements that need to be satisfied as we go through the process.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
No, it's really a mix of both. I mean, most of our customers have been on the record as of many of the experts that at least for a number of years, this will probably be a recurring seasonal vaccine as the vaccine itself is adopted to new strains. And at the same time, we believe that the recognition of our technical capability bodes well for the broader supply in biotech, large molecule drugs, as well as traditional flu vaccines and treatments in general that are injected.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Managing assets like that is kind of what I think we do best. And there are so many different ways that we can create value, from the way the wells are drilled, the way the wells are completed, the marketing arrangements. And it also gives us the opportunity with those additional assets coming in.
We have way more flexibility on what we can dispose of and how we can high-grade our portfolio. So it gives us the opportunity to do what I think we're really good at from an operation standpoint but also from property management. And the swaps and trades, we have a dedicated group around that, and they can create a lot of value in the basin. All the operators are trying to get out of each other's way and not have so much outside operated and create longer lateral drilling opportunities, all kind of things like that.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
We're referring to it as southeastern in the United States at the moment.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. So Todd, as you know, Enterprise is really our initial product, aside from our -- just the storage management piece, where there's no technology. And we've been working on that business for a few years, and it's really a longer sales cycle because you're really focused on larger corporations who need that product. And we're now starting to talk about Enterprise as being almost our mature product compared to Lightspeed because we are starting to see the traction.
The word is getting out. This particular contract was an RFP that our team was able to bid on. And it was an RFP that none of the other storage companies would know about it or bid on it. We're really competing with some other types of logistics companies. And it was not a slam dunk that we would win it. Even though we had them as an initial customer, they were working with us for a while. But this is a big jump, 300 more spaces, almost double the number of current spaces we have entirely, not totally double, but close.
So a very significant win for us. We're very excited about it. This particular contract, it will roll out over the course of this year. It takes some time to work with the client and get it up all and running. But when it's all done and implemented, the fee income should be about $2 million a year. It's a multiyear contract. And on top of that, we would get the premium right as well.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Primarily UK and Spain, but we are certainly looking at other geographies that we have identified as core to our expansion objectives, but it is primarily in the UK and in Spain.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I think that that is roughly true, except for the impact of single-family mortgage. When we're talking about those numbers, that's sort of the core expenses. If you remember the discussion, right, as a core run rate, subject to higher levels of mortgage volumes, which we are expecting to extend through this year and our view of that expansion since that last discussion has elongated. So what does that mean for this year, we're expecting our noninterest expense, inclusive of the impact of mortgage to be a little above that number.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks. Thank you for the questions. Jackie. We're very happy with the recruiting process for a full time CMO.
Although I have to say that we could not have been luckier than to have Edwina Baskin-Bey join us as an acting CMO she kindly did, while this search was under way. She has been a spectacular addition to the team. We do, we are getting great candidates. And we expect to be in a position to announce a full time CMO recruit with extensive oncology experience sometime in the near future.
But as you know, of course, that sort of recruiting is only finished with the signing of the very last document. So with Jackie, your question on mantle cell lymphoma is basically when do we think we'll be ready to continue our dialogue with the FDA about a potential registration path and the answer to that question is now. We are continuing our dialogue with the FDA, about potential accelerated approval and full approval alternatives. And if those discussions are timely, then we would hope to be able to have something to discuss with you in the second half of this year.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Very good question actually because what we've seen is that given we were a first mover in this product, and as far back as the third quarter of 2020 when we bought our own pools and then help structure these additional purchases that we've done totaling 3.7 billion thus far to date, I would say that the economics were certainly more attractive if you were in the first-mover stage, and the economics have really waned to the point that we would not be pursuing additional purchases at these levels.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, thanks for the question, Kevin. This is Scott. There's a couple of factors. When we look at the fourth quarter that we mentioned on the call, they're really driving that sequential change in the core business. The first one is when we look at the molecular kits business, some of our larger and more consumer-focused customers there changed the timing of some of their ordering patterns, where they took more products in the third quarter. And so we would anticipate that that portion of the business being down in the fourth quarter. The second factor is just when you look at the COVID molecular collection kits, we are modeling that business being down sequentially. As I stated on the call, that's potentially a conservative assumption given some of the conversations we've had with our customers, but we feel it's prudent right now, just given what we know in terms of the outlook. And so those are really the two factors outside of InteliSwab that are driving kind of the core piece downwards on a sequential basis.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
That's right.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi, everyone. I guess a question on development. I was wondering, in terms of the incremental development starts that you announced and even just thinking about how you're thinking about development going forward. How much is that going to be weighed toward suburban projects? I know that is a lot of the current pipeline. A little perspective there would be great.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, OK. So the PBND clear out, we generally see our partners look to flush out concentrate and dore leading into the year-end, calendar year-end. So we generally would expect that PBND would be reduced at December 31. We've seen volatility in that in the past, so it's very difficult to estimate with any type of certainty.
But suffice it to say that we would expect that PBND would decrease leading into December 31. The second question was the payment relative to Salobo 3, I think. With the pushout of the ramping up to the second half of next year of that line, that new line, we would expect that Vale would satisfy the completion test that gives rise to the payment in 2023 now. So we estimate that the payment we will make relative to that would be in the range of 550 to $650 million, and that payment would be made in 2023.
And then I wasn't sure what the question --

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. Thanks. Good morning, Everyone. Amit, I was hoping maybe I was hoping you can give us some context on inflation, just kind of the key buckets and how you see that playing out. And then just, Steve, if I could throw in a question to you just strategically and just philosophically. We're obviously seeing a lot of onetime events that are causing a lot of disruption, but these onetime events feel like they just keep on happening. So I wanted to get your kind of thoughts on capex. And does it make sense to just kind of have a super cycle in the near term just to automate as much as possible and just really evolve the infrastructure to be really ready for handling these types of shocks? Thanks.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. Thanks, Doug. Now, as far as Q2 run rate is concerned, if you look back the last few quarters, we've not done a great job of nailing the impact of COVID. It has -- we've generally overperformed our guidance range.
I think last quarter, we had kept the same process, coming off some very high volumes for the last prior four quarters. And really, the only difference I see in Q2 versus Q1 and before is the year-over-year comp, which we had factored in, but also the increase in mobility. I think the impact of people getting vaccinated and getting out in the world, not only shopping off-line, but also living life and getting out, it takes away from shopping time. It's a good phenomenon and it's great.
And we just have to appropriately gauge our run rate going forward. So Prime Day was very successful. We passed the record set in last fall's Prime Day, which was a very different time of year to have Prime Day and started to bump up against early holiday shopping. So we're really pleased.
And again, I think it was a great day for -- then for third-party sellers, as I pointed out.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
No, very clearly, it's a question of opportunities. A week before we did the Suezmax, we were bidding on two VLCCs. We had bid the price that we thought was creating the most value. We didn't get those.
They went to someone else at a price that we were not prepared to pay. So, it demonstrates that it is not a question of which size, it's more a question of what makes more sense in terms of a return.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
All right. Thank you, Sarah. I'd like to just start by giving a shout out to our Plexus team members globally and thank them for all their hard work. They continue to perform exceptionally well despite challenging circumstances that are around us today. And again, thank you to everybody who joined our call today. We certainly appreciate your support and your interest in Plexus.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Don.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. So whenever you do this, you -- so that we had to -- we haven't had disclosed the data cut off, but there was the data cut-off in the past, because you have to analyze all the data, get the data and from around the world, remember there was a global study here and multiple other studies. So there is a definite data cut-off that's in there. What happens though in that standard? Usually what happens is that 120 days after submission, you provide an update on the data that you have accumulated since the filing to the agency. And certainly we will do that as well.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning, thanks for taking my question. Just -- I just have one really. On distribution and loyalty. So 2020 has obviously been a very strange year just because the denominator was so unusual and low. But yourself, Marriott, Hilton and Hyatt, all showed loyalty contribution kind of going down. I thought yours might be a little bit more resilient just because of the nature of the business travel that you have more on a lower end to not be rude about it. Can you just talk about what the main factors were within that? And how does that found with the normal recovery? Does it stay a bit lower? And what does that -- what are the kind of derivative impacts that, that can have going forward?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Great, thanks for taking my question and thanks to the whole team for all the added color today and like my predecessor analyst, a special thanks to Soma for all of her color. Soma, I may need to replay parts of your prepared remarks today at two-third speed so I can absorb it all. And our ability to process information clearly slower in years, but if we could just dive into a couple of things, I'm trying to get a hold on. So -- and I get it so we're talking about the very earliest days. It's a very flash time point than the launch. Things do sound like they're going well, but $600,000 in sales through that very end of March. I believe if I have my notes down correct, you guys are estimating that's about 30 patients that you've treated maybe some context on that number. I know it's a month's of early data but like are we 2%, 20%, 40%.
And then you also, I believe, again, I've got to read my own piece of written notes, but 60-40 on the community academic breakdown and 60-30-10 on the net D the commercial and government breakdown like, can you give us some context on where those are and where we think they need to be, like I mean again, right. So, it's just the first few weeks, we're all going to over analyze it. That's what we do, but sort of where are we on those, if you could give us some?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. So Mig, I'd say that, to add what Aaron on said, because of the supply chain issues and everything, it's a moving target to some extent. We're not going to comment on the quarterly margins, which is why I only gave that. I'd say, generally speaking, we are going to be a bit higher in Q4.
We anticipate being a bit higher in Q4 just because of the way we do things. But I wouldn't say it's going to be a significant difference between the two. And I think that from a margin impact, we're going to see kind of the flow-through of costs impacting Q3 and Q4. And that could be equally throughout the year because of the amount of backlog we have going through for the remainder of the year.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning. Thanks so much for taking the questions. How is the competitive environment shaking out as the recovery has ramped up? Have you seen any smaller distributors finally start to go out of business, given less flexibility on inventory and fluctuations in food-away-from-home demand? And have you seen any meaningful wallet share increases in your independent customers? Thanks.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
It's a great question, Faiza, particularly because devices make up nearly 30% of our revenue and are really a key growth driver. As we've come into this year, we continue to see a lot of strength in those devices, not necessarily impacted by the sort of new normal that we're starting to see around the world with devices. And fortunately, we have a real strong pipeline. We just launched Boost. We'll be connecting these devices and making them more interactive, I think, with customers going forward. So we see that trend continuing to play very, very strong. Ryan, maybe you would add something to that.

    Prediction (one of UP, DOWN, SAME): UP